Abstract
Purpose :
Multicentre trials have demonstrated the efficacy of Aflibercept in the management of nAMD. There is no long-term real-life data available on patient outcomes at 5 years after the initiation of treatment. We carried out a retrospective study of visual and anatomical outcomes 5 years after initiating Aflibercept therapy.
Methods :
Retrospective analysis of 100 consecutive treatment naive eyes receiving intra-vitreal Aflibercept for the treatment of nAMD (April 2013-November 2018), at a single specialised ophthalmic centre in North East of England, UK. In the first year, fixed dosing regimen was adhered to, with three monthly loading doses and a bimonthly regimen thereafter. Pro re nata (PRN) dosing regimen was followed after the first year. Visual acuity, OCT features, follow-up period and number of treatments received were noted.
Results :
100 eyes (96 patients) receiving Aflibercept treatment for nAMD were included. Mean age at presentation was sent to 79.6 years with 60% diagnosed as occult choroidal neovascular membrane. Mean follow-up period was 199.5 weeks (STD 77.5 weeks). 26 patients (27 eyes) had died at the time of this analysis. Nine eyes were switched to Ranibizumab. Stability of vision was achieved by 82% of patients. 79% patients maintained stability of vision at 12 months and 48% at 5 year (16% patients gaining greater than15 letters at 5 years). On average, patients received 13.98 injections. The mean reduction in central macula thickness (CMT) from baseline was 107.7 microns (SD 139.68 microns) and from 12 months was 130.67 microns (SD 159.24 microns). 65% of OCT’s were noted to be dry at last follow up.
Conclusions :
The real-life outcomes confirmed the long-term effectiveness of Aflibercept in the treatment of nAMD after four years treatment
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.